Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise medical treatment of Cushing's disease with pasireotide alone or in combination
2006-004080-55Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Jan 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR, cabergoline and ketoconazole in Corticotropin adenoma (ACTHoma), sponsored by Erasmus MC. Primary endpoint: Normalization of cortisol production. Started Jan 2007; status: active.
02
Drugs
pasireotide LARcabergolineketoconazole
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2006-004080-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004080-55.